Compare NVR Inc. Common Stock (NVR) vs Pfizer Inc (PFE) Price & Performance

NVR trades at $5,797.61, up 0.83% today, with a P/E of 15.07 and P/S of 1.79. Recent earnings missed estimates in Q1 and Q2 2026, with revenue and net income projected to decline in 2026. The stock faces headwinds from margin pressure and softer homebuyer demand, as highlighted by Zacks naming it Bear of the Day on October 9, 2026. Despite this, strong profitability metrics like a 31.54% ROE and consistent cash flow from operations support its financial resilience.

The outlook is cautious due to earnings misses and a projected revenue drop, but the asset-light model and share buybacks provide stability. Risks include mortgage rate sensitivity and competitive pressures, while analyst consensus leans neutral with a $6,550 price target. Patient investors may find value if housing demand recovers.

Pfizer (PFE) trades at $28.37, down slightly by 0.11% on the day, with a bullish technical signal from moving averages. The company maintains strong profitability with a 73.18% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on obesity and oncology pipeline developments, positioning for a catalyst-rich 2026.

Pfizer presents a mixed outlook with stable revenue around $63B but declining net income projections for 2026. The stock trades near analyst consensus target of $29.17, offering modest upside potential. Key risks include patent cliffs and competitive pressures, while the dividend yield and pipeline progress provide defensive appeal for income-focused investors.